… of new oral anticoagulants that target either factor Xa or thrombin… and edoxaban, the oral
factor Xa inhibitors in the most advanced … Therefore, development of the oral factor Xa inhibitors …

… and its limited roles outside of coagulation, Factor Xa has emerged as an attractive target
for … of research into small-molecule, oral, direct Factor Xa inhibitors, and several are now in …

… the parenteral direct thrombin inhibitors, the development of the indirect factor Xa inhibitor, …
has resulted in oral direct inhibitors of both thrombin (factor IIa) and factor Xa. The inverted …

… This article will give an overview of the oral, direct Factor Xa inhibitor … indirect Factor Xa
inhibitor (fondaparinux), other direct Factor Xa inhibitors (apixaban and edoxaban), and the direct …

… A range of new oral anticoagulant drugs are currently in late-stage clinical development,
including oral factor Xa inhibitors and an oral direct thrombin inhibitor. The research …

… A number of novel oral anticoagulants that directly target factor Xa or thrombin have been …
apixaban (direct factor Xa inhibitors) and dabigatran etexilate (a direct thrombin inhibitor) have …

… Rivaroxaban (BAY 59-7939) is an oral direct factor Xa inhibitor currently under clinical …
Rivaroxaban is an oral direct factor Xa inhibitor in advanced clinical development. Rivaroxaban …

Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in
a concentration-dependent manner. This review describes the extensive clinical …

… BAY 59–7939 is an oral, direct factor Xa inhibitor in development for … factor Xa inhibitors.
In preclinical studies BAY 59–7939 has demonstrated dose–dependent inhibition of factor Xa …

… rivaroxaban – an oral, direct factor Xa inhibitor – a haemostasis … or chromogenic assays to
measure anti-factor Xa activity, were … Tests were performed with the indirect factor Xa inhibitor …